Mitocon Biopharma has long been recognized as a centre of excellence in pharmacovigilance and lifecycle management, delivering regulatory expertise to trademarked pharmaceutical companies.
Our integrated pharmacovigilance services ensure full compliance and patient safety, offering end- to- end services covering medical Information Call Centre (MICC) 24/7, scientific/medical literature monitoring (MLM), Individual case safety report (ICSR) tracking, processing and submission, signal detection services, aggregate report preparation and submission to relevant regulatory authorities as per marketing authorisation status of respective product.


Dr. Ramulu Garlapati is an experienced medical professional and healthcare leader serving as the Director – Pharmacovigilance and Managing Director of Mitocon. Holding an MBBS degree and bringing over 20 years of experience as a Surgeon with the Government of India, he combines extensive clinical expertise with strong leadership in healthcare operations and patient safety.

Dr. Ramulu Garlapati is an experienced medical professional and healthcare leader serving as the Director – Pharmacovigilance and Managing Director of Mitocon. Holding an MBBS degree and bringing over 20 years of experience as a Surgeon with the Government of India, he combines extensive clinical expertise with strong leadership in healthcare operations and patient safety.
Dr. Ramulu’s expertise in clinical healthcare, safety monitoring, and operational management enables Mitocon to maintain excellence in pharmacovigilance practices while continuously improving quality systems and service delivery. His leadership reflects a strong commitment to medical integrity, healthcare innovation, and organizational growth.
With a deep understanding of clinical practice and drug safety monitoring, Dr. Ramulu plays a critical role in overseeing pharmacovigilance activities, medical evaluation processes, and regulatory compliance initiatives at Mitocon. His medical background and practical healthcare experience contribute significantly to ensuring high standards of patient safety, risk assessment, and quality-focused pharmacovigilance services.
As Managing Director, he is actively involved in guiding the company’s strategic operations, strengthening healthcare partnerships, and supporting the organization’s commitment to delivering reliable, compliant, and scientifically driven solutions to global clients.